🧬 Amycretin

What Is Amycretin?

Amycretin is a novel, long‑acting unimolecular co‑agonist that simultaneously activates glucagon‑like peptide‑1 (GLP‑1) and amylin receptors [citation:1]. It is being developed by Novo Nordisk as a treatment for adults with overweight, obesity, and type 2 diabetes [citation:2].

Unlike combination therapies that are physical mixtures of separate peptides, amycretin is a single molecule engineered to engage both receptors synergistically [citation:1]. This design allows it to leverage the complementary biology of GLP‑1 and amylin, potentially overcoming the efficacy ceilings of current mono‑target therapies [citation:1]. Uniquely, amycretin is being developed for both subcutaneous (once‑weekly) and oral (once‑daily) administration, addressing compliance barriers associated with chronic injections [citation:1].

Mechanism of Action

Amycretin’s dual‑agonist mechanism engages two complementary pathways for metabolic regulation [citation:1][citation:10]:

In preclinical studies, amycretin activated human, mouse, and rat GLP‑1, amylin, and calcitonin receptors in cell‑based systems [citation:4]. In diet‑induced obese rats, amycretin reduced total energy intake by 47% and lowered body weight by 18% over 21 days while maintaining energy expenditure [citation:4]. It also improved insulin sensitivity and histological hallmarks of metabolic dysfunction‑associated steatotic liver disease (MASLD) [citation:4].

Phase 1b/2a Data (Overweight & Obesity)

A Phase 1b/2a randomised, placebo‑controlled trial evaluated once‑weekly subcutaneous amycretin in 125 participants with overweight or obesity (BMI 27.0–39.9 kg/m²) [citation:3].

Key findings from the trial [citation:3][citation:6][citation:7]:

• Estimated weight loss (adherence‑adjusted): 9.7% at 20 weeks (1.25 mg), 16.2% at 28 weeks (5 mg), and 22.0% at 36 weeks (20 mg) [citation:6].
• Absolute weight loss: 24.3% in the 60 mg group vs. 1.1% in placebo at week 36 (P < 0.0001) [citation:3].
• Rapid onset: Weight loss was observed early and continued throughout the trial, with no plateau at the highest doses [citation:1].
• Safety: The safety profile was consistent with GLP‑1 and amylin agonists; gastrointestinal events were most common and largely mild to moderate [citation:3].

Phase 2 Data (Type 2 Diabetes)

A Phase 2 trial (NCT06542874) investigated amycretin in 448 patients with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor [citation:2][citation:11].

Key findings [citation:2][citation:5][citation:11]:

• Subcutaneous amycretin (0.4–40 mg weekly): Dose‑dependent HbA1c reduction of up to 1.8% from a mean baseline of 7.8%; 89.1% achieved HbA1c <7% [citation:2]. Weight loss of up to 14.5% from a mean baseline of 99.2 kg [citation:2].
• Oral amycretin (6–50 mg daily): HbA1c reduction of up to 1.5% from a mean baseline of 8.0%; 77.6% achieved HbA1c <7% [citation:2]. Weight loss of up to 10.1% from a mean baseline of 101.1 kg [citation:2].
• No plateau: For higher doses of both subcutaneous and oral amycretin, no weight‑loss plateau was observed at week 36 [citation:2].
• Glycemic efficacy: All HbA1c improvements were statistically significant versus placebo [citation:2].
• Safety: Consistent with incretin‑based therapies; gastrointestinal events were the most common and mostly mild to moderate [citation:2].

Comparison of Key Outcomes

Safety & Side Effects

Amycretin’s safety profile has been consistent across trials and is comparable to other incretin‑based therapies [citation:2][citation:3].

⚠️ Common Adverse Events

• Gastrointestinal: Nausea, vomiting, diarrhea, and constipation—the most common events, predominantly mild to moderate in severity [citation:3][citation:5].
• Injection‑site reactions: Mild and transient [citation:3].
• Discontinuation rates: A high proportion of participants withdrew from the obesity trial, with a significant number occurring due to reasons unrelated to treatment‑emergent adverse events [citation:3].

📋 Serious Considerations

• No deaths or unexpected safety signals were reported in completed trials [citation:3].
• Long‑term safety data are still being collected; Phase 3 programs will provide larger‑scale safety assessments [citation:2].
• Withdrawal rates: The Phase 1b/2a obesity trial was limited by a high dropout rate, which may affect the generalizability of the results [citation:7].

Regulatory & Development Status

Amycretin is currently investigational and has not received regulatory approval [citation:1].

• Phase 3 plans: Novo Nordisk has announced plans to initiate an extensive Phase 3 development program for amycretin in 2026 for adults with type 2 diabetes [citation:2].
• Ongoing trials: A Phase 2 trial combining amycretin with semaglutide is in development .
• Commercial positioning: Amycretin is seen as a potential successor to semaglutide, helping Novo Nordisk extend its leadership in the obesity and diabetes market beyond semaglutide’s patent expiries (2031–2032) [citation:8].
• Oral formulation: The once‑daily oral formulation is a key differentiator that could improve adherence and accessibility [citation:1].

Amycretin represents a significant advancement in peptide‑based metabolic therapy. By combining GLP‑1 and amylin agonism in a single molecule—available in both subcutaneous and oral formulations—it offers a potentially more effective and convenient option for obesity and type 2 diabetes. The Phase 2 data are encouraging, with weight loss approaching surgical outcomes and robust glycemic control. However, amycretin remains investigational, and Phase 3 trials will be critical to confirm its efficacy, safety, and durability. For clinicians and patients alike, amycretin is a therapy to watch—and one that may redefine the standard of care in metabolic medicine.

❓ FAQs About Amycretin

✧ Written in service of evidence‑based medicine and scientific curiosity ✧